Mesenchymal glioblastoma, a phenotype associated with poor clinical outcomes, is characterized by the expression of CD44 and chitinase 3-like protein 1 (CHI3L1) in mesenchymal glioma stem cells (GSCs). CHI3L1 has been implicated in several oncogenic pathways driving mesenchymal differentiation. However, the role of CHI3L1 as a paracrine modulator of GSC states, as well as the transcriptional regulatory network induced by CHI3L1 in GSCs, remains unknown.
Researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College presented the discovery and preclinical evaluation of farnesoid X receptor (FXR) antagonists.
Researchers from NYU Grossman School of Medicine reported on a new strategy intended to provide long-term protection against the SARS-CoV-2 virus using an experimental decoy.
Researchers from Atux Iskay LLC assessed whether reactivation of protein phosphatase 2A (PP2A) using a small-molecule PP2A activator, ATUX-1215, could counter TGF-β signaling in preclinical models of idiopathic pulmonary fibrosis (IPF).
By interfering with mitochondrial plasticity, researchers have succeeded in attenuating brain metastases of HER2-expressing breast tumors. The authors wrote that their findings “highlight targeting mitochondrial dynamics is a viable therapeutic opportunity to limit both brain tumors and metastasis.”
A group of German and French scientists has identified 15 genetic variants in a proteasome protein complex that are related to neurodevelopmental delay and also alter interferon type 1-mediated immune signaling. The finding contributes to the diagnosis of this neurological disorder and gives an opportunity for the development of therapies in patients who have these mutations.
With overuse of opioids – the standard of care for many chronic pain cases – becoming something of an epidemic in the U.S., the availability of an alternative, non-opioid analgesic is a big draw. Established in 2021, Adolore Biotherapeutics Inc. is one company that could provide the answer, with its locally and long-acting gene therapies potentially providing a breakthrough that “knocks everybody’s socks off.”
National Institute of Pharmaceutical R&D Co. Ltd. has identified Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of cancer and viral infections.
RSS
